A Safety Study Of Pregabalin In Fibromyalgia

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety of pregabalin in patients with fibromyalgia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites.

• Patients must complete the double-blind study.

Exclusion Criteria:

• Patients who experienced a serious adverse event during the previous fibromyalgia study, which was determined to be related to the study medication.